Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, discusses the development of allogeneic gamma delta (γδ) T cells. Whilst there has previously been a focus on autologous therapies such as LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, current attention is directed towards allogeneic therapies. The emergence of γδ T cells have been beneficial as they do not cause graft versus host disease (GvHD) and are already HLA matched between donor and patient. Dr Liter additionally highlights a proprietary Tc Buster Transposon system that enables expansion of the Vδ1 and Vδ2 subtypes of γδ T cells. This interview took place at Advanced Therapies Week 2022.
Jeff Liter is an employee of Luminary Therapeutics.